Famotidine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Famotidine: From Peptic Ulcer Disease to Duodenogastric Reflux
One-Sentence Summary
Famotidine is a histamine H2-receptor antagonist, conventionally used to suppress gastric acid secretion in conditions such as peptic ulcer disease. The TxGNN model predicts a possible additional role in Duodenogastric Reflux, but this specific prediction is currently supported by 0 clinical trials and only 2 publications, placing it at a very early, hypothesis-generating stage of evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Peptic ulcer disease / acid-related gastrointestinal disorders (general H2-receptor antagonist use; no drug-specific licensed indication text is available in this evidence pack) |
| Predicted New Indication | Duodenogastric Reflux |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L3 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold (flagged internally as “Research Question” — early-stage signal only) |
Why is This Prediction Reasonable?
Detailed mechanism of action data for this candidate is not available in the evidence pack (a High-severity data gap). Based on well-established pharmacological knowledge, famotidine belongs to the histamine H2-receptor antagonist class, and its acid-suppressing efficacy in peptic ulcer disease and related acid-hypersecretory conditions is well documented; mechanistically, reducing gastric acid output could plausibly extend some benefit to other reflux-type conditions.
However, the specific mechanistic link proposed for duodenogastric reflux is weak. Duodenogastric reflux is primarily driven by retrograde flow of bile and pancreatic juice into the stomach, rather than by gastric acid hypersecretion. Acid suppression may relieve secondary acid-related symptoms, but it does not address the underlying pathophysiology of bile/pancreatic reflux. Consequently, while the TxGNN score is very high, the biological rationale for direct therapeutic benefit in this indication is limited, and the prediction should be regarded as a research hypothesis rather than a clinically actionable signal at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12532466 | 2003 | Cohort/Clinical study | World Journal of Gastroenterology | Investigated the effect of famotidine on gastroesophageal reflux (GER) and duodeno-gastro-esophageal reflux (DGER) in critically ill patients, exploring possible mechanisms and relevant contributing factors. |
| 16259441 | 2004 | Review | Eksperimental’naia i klinicheskaia gastroenterologiia (Experimental & Clinical Gastroenterology) | Reviewed efficacy of famotidine 20 mg twice daily at early stages of gastroduodenal reflux disease, based on clinical and endoscopic assessment (Savary–Miller grades 0–1). |
UK Market Information
No UK marketing authorisations are currently recorded for Famotidine in this evidence pack (0 licences; market status: Not marketed). No product name, dosage form, or licensed indication text is therefore available to summarise here.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: this evidence pack flags a Blocking data gap — SmPC-equivalent warnings/contraindications data has not yet been retrieved — which by itself prevents this candidate from completing even a preliminary (S1) safety assessment.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The mechanistic rationale for duodenogastric reflux is biologically weak (acid suppression does not target the bile/pancreatic-driven pathology), and no clinical trials support this specific indication — only two low-tier publications (a clinical cohort study and a review) exist.
- A Blocking data gap on safety/warning label data means this candidate cannot yet proceed past the initial safety screening stage regardless of efficacy evidence.
To proceed, the following is needed:
- Retrieval of SmPC-equivalent warnings, contraindications, and prescribing information (currently a Blocking data gap)
- Confirmation of famotidine’s mechanism of action from DrugBank or an equivalent source (currently a High-severity data gap)
- Dedicated mechanistic or clinical studies addressing bile/pancreatic reflux components of duodenogastric reflux, rather than acid-only endpoints
- Confirmation of UK marketing/licensing status, since no authorisations are currently on record
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.